Last reviewed · How we verify
AN2690 Solution, 5.0%
AN2690 Solution is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNMA1.
AN2690 Solution is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNMA1. Used for Treatment of focal epilepsy.
At a glance
| Generic name | AN2690 Solution, 5.0% |
|---|---|
| Sponsor | Pfizer |
| Drug class | Sodium-activated potassium channel blocker |
| Target | KCNMA1 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the KCNMA1 channel, AN2690 Solution is thought to reduce the excitability of neurons and potentially alleviate symptoms of certain neurological disorders. The exact mechanism of action is not fully understood, but it is believed to involve a reduction in the frequency and amplitude of action potentials.
Approved indications
- Treatment of focal epilepsy
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Cumulative Irritation Test (PHASE1)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2690 Solution, 5.0% CI brief — competitive landscape report
- AN2690 Solution, 5.0% updates RSS · CI watch RSS
- Pfizer portfolio CI